PE20010487A1 - Vacuna de rotavirus - Google Patents
Vacuna de rotavirusInfo
- Publication number
- PE20010487A1 PE20010487A1 PE2000000825A PE0008252000A PE20010487A1 PE 20010487 A1 PE20010487 A1 PE 20010487A1 PE 2000000825 A PE2000000825 A PE 2000000825A PE 0008252000 A PE0008252000 A PE 0008252000A PE 20010487 A1 PE20010487 A1 PE 20010487A1
- Authority
- PE
- Peru
- Prior art keywords
- nucleotides
- sequence
- version
- rotavirus
- adenine
- Prior art date
Links
- 229940124859 Rotavirus vaccine Drugs 0.000 title 1
- 241000702670 Rotavirus Species 0.000 abstract 3
- 239000002773 nucleotide Substances 0.000 abstract 3
- 229930024421 Adenine Natural products 0.000 abstract 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- 229960000643 adenine Drugs 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- 230000000977 initiatory effect Effects 0.000 abstract 2
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 229920000297 Rayon Polymers 0.000 abstract 1
- 206010067470 Rotavirus infection Diseases 0.000 abstract 1
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12351—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9919468.0A GB9919468D0 (en) | 1999-08-17 | 1999-08-17 | Vaccine |
| GBGB9927336.9A GB9927336D0 (en) | 1999-11-18 | 1999-11-18 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010487A1 true PE20010487A1 (es) | 2001-06-23 |
Family
ID=26315853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000825A PE20010487A1 (es) | 1999-08-17 | 2000-08-15 | Vacuna de rotavirus |
Country Status (42)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302173B6 (cs) * | 1999-08-17 | 2010-11-24 | Smithkline Beecham Biologicals S. A. | Oslabená populace lidského rotaviru |
| US6592869B2 (en) | 1999-08-24 | 2003-07-15 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
| GB0020089D0 (en) * | 2000-08-15 | 2000-10-04 | Smithkline Beecham Biolog | Vaccine Composition |
| KR20030026654A (ko) * | 2001-09-26 | 2003-04-03 | 주식회사 씨트리 | 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용 |
| PL2272532T3 (pl) | 2003-09-02 | 2016-07-29 | Glaxosmithkline Biologicals Sa | Szczepionka rotawirusowa |
| GB0414787D0 (en) | 2004-07-01 | 2004-08-04 | Glaxosmithkline Biolog Sa | Method |
| GB0503337D0 (en) * | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| JP5519934B2 (ja) * | 2005-08-17 | 2014-06-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 異型交差防御を誘導するロタウイルスワクチン |
| WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| KR101051986B1 (ko) * | 2006-09-28 | 2011-07-26 | 중앙대학교 산학협력단 | 인간로타바이러스 및 이를 이용한 백신 조성물 |
| DK2099485T3 (en) * | 2006-11-03 | 2018-05-22 | Alphavax Inc | Alphavirus and alphavirus replica particle formulations and associated methods |
| EP2236617A1 (en) | 2009-03-31 | 2010-10-06 | Leukocare Ag | Methods of terminal sterilization of biofunctional compositions |
| CA3121654A1 (en) | 2009-05-12 | 2010-11-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | New human rotavirus strains and vaccines |
| US9598676B2 (en) | 2009-07-13 | 2017-03-21 | Bharat Biotech International Limited | Composition useful as rotavirus vaccine and a method therefor |
| FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
| CN110227152A (zh) | 2012-04-23 | 2019-09-13 | 巴拉特生物技术国际有限公司 | 轮状病毒疫苗组合物及其制备方法 |
| NZ631348A (en) * | 2012-08-27 | 2017-02-24 | Murdoch Childrens Res Inst | Modified human rotaviruses and uses therefor |
| PL3299384T3 (pl) * | 2015-05-21 | 2022-01-24 | Xiamen University | Skrócone białko vp4 rotawirusa i jego zastosowanie |
| CN108431214B (zh) | 2015-10-05 | 2022-03-01 | 美国政府(由卫生和人类服务部的部长所代表) | 人轮状病毒g9p[6]毒株和作为疫苗的用途 |
| EP3373965A1 (en) * | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
| WO2017106115A1 (en) * | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Thermally stable rotavirus vaccine formulations and methods of use thereof |
| MA44557B1 (fr) | 2016-06-16 | 2021-11-30 | Bharat Biotech Int Ltd | Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer |
| GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
| CN110856493B (zh) * | 2018-08-20 | 2022-02-25 | 中国烟草总公司黑龙江省公司牡丹江烟草科学研究所 | 一种植物病毒弱毒疫苗组合物、弱毒疫苗保存方法及其应用 |
| WO2024242174A1 (ja) * | 2023-05-24 | 2024-11-28 | 国立大学法人大阪大学 | 一回感染性ロタウイルスおよびその利用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5927323B2 (ja) | 1976-10-12 | 1984-07-05 | 花王株式会社 | 歯みがき組成物 |
| US4341763A (en) * | 1981-03-10 | 1982-07-27 | Smithkline-Rit | Methods of vaccinating humans against rotavirus infection |
| US4571385A (en) * | 1983-06-27 | 1986-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors |
| US4624850A (en) | 1984-02-09 | 1986-11-25 | Royal Children's Hospital Research Foundation | Live attenuated human rotavirus vaccine |
| US5626851A (en) * | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
| EP0557427B1 (en) * | 1990-11-16 | 1998-08-26 | Children's Hospital Medical Center | Human rotaviruses, vaccines and methods |
| US5471385A (en) * | 1992-05-21 | 1995-11-28 | Tsubakimoto Chain Co. | Routeless guiding method for moving body |
| US5773009A (en) | 1994-04-15 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Rotavirus strain G9P11 |
| AU3125795A (en) | 1994-07-11 | 1996-02-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Attenuated human rotavirus vaccine |
| US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| DE69738271T2 (de) * | 1996-09-26 | 2008-08-28 | Merck & Co., Inc. | Rotavirus-impfstoff |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| CZ302173B6 (cs) * | 1999-08-17 | 2010-11-24 | Smithkline Beecham Biologicals S. A. | Oslabená populace lidského rotaviru |
-
2000
- 2000-08-15 CZ CZ20020522A patent/CZ302173B6/cs not_active IP Right Cessation
- 2000-08-15 DZ DZ003219A patent/DZ3219A1/fr active
- 2000-08-15 SK SK243-2002A patent/SK287261B6/sk not_active IP Right Cessation
- 2000-08-15 CA CA2379196A patent/CA2379196C/en not_active Expired - Lifetime
- 2000-08-15 DE DE2000628390 patent/DE122006000026I1/de active Pending
- 2000-08-15 IL IL14792600A patent/IL147926A0/xx not_active IP Right Cessation
- 2000-08-15 BR BRPI0013357A patent/BRPI0013357B8/pt not_active IP Right Cessation
- 2000-08-15 OA OA1200200054A patent/OA12312A/en unknown
- 2000-08-15 PL PL354135A patent/PL205550B1/pl unknown
- 2000-08-15 TR TR2002/00420T patent/TR200200420T2/xx unknown
- 2000-08-15 UA UA2002021196A patent/UA77388C2/uk unknown
- 2000-08-15 HU HU0203335A patent/HU228975B1/hu active Protection Beyond IP Right Term
- 2000-08-15 DE DE60028390T patent/DE60028390T2/de not_active Expired - Lifetime
- 2000-08-15 MX MXPA02001648A patent/MXPA02001648A/es active IP Right Grant
- 2000-08-15 MY MYPI20003730 patent/MY133158A/en unknown
- 2000-08-15 SI SI200030846T patent/SI1212084T1/sl unknown
- 2000-08-15 PT PT00958452T patent/PT1212084E/pt unknown
- 2000-08-15 AT AT00958452T patent/ATE327765T1/de active
- 2000-08-15 EP EP00958452A patent/EP1212084B1/en not_active Expired - Lifetime
- 2000-08-15 HK HK02108459.5A patent/HK1046860B/en not_active IP Right Cessation
- 2000-08-15 EA EA200200142A patent/EA005952B1/ru not_active IP Right Cessation
- 2000-08-15 NZ NZ517131A patent/NZ517131A/en not_active IP Right Cessation
- 2000-08-15 ES ES00958452T patent/ES2260046T3/es not_active Expired - Lifetime
- 2000-08-15 WO PCT/EP2000/007965 patent/WO2001012797A2/en not_active Ceased
- 2000-08-15 AU AU69961/00A patent/AU767885B2/en not_active Expired
- 2000-08-15 PE PE2000000825A patent/PE20010487A1/es not_active Application Discontinuation
- 2000-08-15 DK DK00958452T patent/DK1212084T3/da active
- 2000-08-15 AP APAP/P/2002/002424A patent/AP1768A/en active
- 2000-08-15 AR ARP000104215A patent/AR029643A1/es active IP Right Grant
- 2000-08-15 US US10/049,192 patent/US7285280B1/en not_active Expired - Lifetime
- 2000-08-15 KR KR1020027002036A patent/KR100695599B1/ko not_active Expired - Lifetime
- 2000-08-15 JP JP2001517682A patent/JP2003507040A/ja active Pending
- 2000-08-15 CN CNB008143498A patent/CN100379451C/zh not_active Expired - Lifetime
- 2000-08-16 UY UY26297A patent/UY26297A1/es not_active IP Right Cessation
- 2000-08-17 CO CO00061886A patent/CO5580165A1/es active IP Right Grant
- 2000-11-20 TW TW089124533A patent/TWI283270B/zh not_active IP Right Cessation
-
2002
- 2002-01-31 IL IL147926A patent/IL147926A/en active Protection Beyond IP Right Term
- 2002-02-15 MA MA26521A patent/MA25489A1/fr unknown
- 2002-02-15 BG BG106417A patent/BG65314B1/bg unknown
- 2002-02-15 NO NO20020763A patent/NO328112B1/no not_active IP Right Cessation
-
2006
- 2006-06-12 FR FR06C0018C patent/FR06C0018I2/fr active Active
- 2006-06-13 CY CY20061100784T patent/CY1106103T1/el unknown
- 2006-06-14 LU LU91251C patent/LU91251I2/fr unknown
- 2006-06-26 NL NL300233C patent/NL300233I2/nl unknown
- 2006-07-28 CY CY200600004C patent/CY2006004I2/el unknown
-
2007
- 2007-08-14 JP JP2007211282A patent/JP2007319164A/ja not_active Withdrawn
- 2007-08-22 US US11/843,256 patent/US7790179B2/en not_active Expired - Fee Related
- 2007-08-23 US US11/843,815 patent/US20080063662A1/en not_active Abandoned
- 2007-10-19 US US11/875,286 patent/US7790180B2/en not_active Expired - Fee Related
-
2008
- 2008-01-09 IL IL188686A patent/IL188686A0/en unknown
-
2010
- 2010-05-19 NO NO2010011C patent/NO2010011I2/no unknown
- 2010-09-28 JP JP2010217093A patent/JP5474720B2/ja not_active Expired - Lifetime
-
2013
- 2013-11-29 HU HUS1300072 patent/HUS1300072I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010487A1 (es) | Vacuna de rotavirus | |
| MX9204885A (es) | Composicion de vacuna que comprende virus del sindrome de infertilidad y respiratorio de los cerdos. | |
| BR9705009A (pt) | Vírus da síndrome porcina reprodutiva e respiratória de vida atenuada processo para preparação do mesmo vacina para a proteção de porcos contra a infecção pelo vírus e processo para preparação da vacina | |
| ES2170234T3 (es) | Vacuna contra el virus prrs (sindrome reproductor y respiratorio porcino). | |
| ES2165405T3 (es) | Cepas de vacuna europeas del virus del sindrome reproductor y respiratorio porcino (prrsv). | |
| RU98101129A (ru) | Низкопатогенные живые вакцины вируса prrs и способы их получения | |
| BR0111366A (pt) | Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv) | |
| ES2035818T3 (es) | Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso. | |
| ES2121000T3 (es) | Composicion utilizada como agente terapeutico contra enfermedades hepaticas virales cronicas. | |
| BR0204470A (pt) | Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos | |
| GR3024173T3 (en) | Assembled viral particles and their use in a vaccine to rotaviral disease. | |
| MXPA01006214A (es) | Composicion inmunogenica multivalente que contiene una preparacion de virus de influenza y una composicion de subunidad del virus sincicial respiratorio. | |
| ES2052042T3 (es) | Procedimiento de estabilizacion de las vacunas y asociaciones de vacunas de virus atenuados conservadas en forma liofilizada, y composiciones obtenidas. | |
| HUT63459A (en) | Blood factors produced by recommbinant process, process for expressing them, as well as recombinant vaccine viruses used in the process | |
| BR0207988A (pt) | Cepas atenuadas vivas de vìrus de prrs | |
| AR006023A1 (es) | Vacuna contra el sindrome reproductivo y respiratorio porcino | |
| NO970847L (no) | 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel | |
| ES2032339T3 (es) | Procedimiento para preparar nuevos compuestos de indolilpiperidina. | |
| ES2061603T3 (es) | Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos. | |
| MXPA94008605A (es) | Replicacion de un virus no patogenico que expresalas glicoproteinas de la envoltura del virus de ladiarrea viral bovina (bvdv). | |
| CA2116355A1 (en) | Infectious bovine rhinotracheitis virus mutants and vaccines | |
| ES2054230T3 (es) | Un proceso para la preparacion de un enterovirus o rinovirus atenuado. | |
| CA2363493A1 (en) | Attenuated forms of bovine viral diarrhea virus | |
| MX9203436A (es) | Vacuna para la enfermedad de marek de serotipo 1 revertida y atenuada. | |
| ES2061165T3 (es) | Vacuna para la proteccion de las aves de corral frente a la enfermedad de marek. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |